Claim your guide now: Small Cap Multibaggers in the Making
Here is the latest financial fact sheet of GSK PHARMA. For more details, see the GSK PHARMA quarterly results and GSK PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 0.3 |
No. of shares | m | 169.41 |
1 Week | % | -1.0 |
1 Month | % | -9.7 |
1 Year | % | 55.2 |
52 week H/L | Rs | 2,650.0/1,228.0 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
GSK PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 3,595 | 1,745 | 1,805 | 1,917 | 1,684 | |
Low | Rs | 1,253 | 1,046 | 1,155 | 1,400 | 1,231 | |
Sales per share (Unadj.) | Rs | 184.6 | 190.3 | 172.7 | 193.5 | 191.9 | |
Earnings per share (Unadj.) | Rs | 26.3 | 5.5 | 17.0 | 22.5 | 35.9 | |
Diluted earnings per share | Rs | 26.3 | 5.5 | 17.0 | 22.5 | 35.9 | |
Cash flow per share (Unadj.) | Rs | 29.2 | 10.4 | 21.6 | 26.5 | 39.8 | |
Dividends per share (Unadj.) | Rs | 20.00 | 40.00 | 30.00 | 90.00 | 32.00 | |
Adj. dividends per share | Rs | 20.00 | 40.00 | 30.00 | 90.00 | 32.00 | |
Avg Dividend yield | % | 0.8 | 2.9 | 2.0 | 5.4 | 2.2 | |
Book value per share (Unadj.) | Rs | 126.3 | 107.5 | 87.3 | 157.2 | 102.9 | |
Adj. book value per share | Rs | 126.3 | 107.5 | 87.3 | 157.2 | 102.9 | |
Shares outstanding (eoy) | m | 169.41 | 169.41 | 169.41 | 169.41 | 169.41 | |
Price / Sales ratio | x | 13.1 | 7.3 | 8.6 | 8.6 | 7.6 | |
Avg P/E ratio | x | 92.2 | 253.7 | 87.3 | 73.8 | 40.6 | |
P/CF ratio (eoy) | x | 83.1 | 134.4 | 68.5 | 62.6 | 36.7 | |
Price / Book Value ratio | x | 19.2 | 13.0 | 17.0 | 10.6 | 14.2 | |
Dividend payout | % | 76.1 | 727.0 | 176.9 | 400.4 | 89.2 | |
Avg Mkt Cap | Rs m | 410,644 | 236,440 | 250,695 | 280,960 | 246,858 | |
Total wages/salary | Rs m | 5,372 | 6,286 | 6,162 | 6,102 | 5,950 |
GSK PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 31,281 | 32,244 | 29,256 | 32,780 | 32,517 | |
Other income | Rs m | 1,023 | 790 | 1,106 | 758 | 1,007 | |
Total revenues | Rs m | 32,304 | 33,034 | 30,362 | 33,538 | 33,524 | |
Gross profit | Rs m | 6,295 | 3,158 | 4,255 | 7,735 | 8,033 | |
Depreciation | Rs m | 486 | 827 | 786 | 682 | 658 | |
Interest | Rs m | 6 | 63 | 35 | 20 | 18 | |
Profit before tax | Rs m | 6,827 | 3,058 | 4,540 | 7,790 | 8,364 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 2,373 | 2,125 | 1,667 | 3,983 | 2,288 | |
Profit after tax | Rs m | 4,454 | 932 | 2,873 | 3,808 | 6,076 | |
Gross profit margin | % | 20.1 | 9.8 | 14.5 | 23.6 | 24.7 | |
Effective tax rate | % | 34.8 | 69.5 | 36.7 | 51.1 | 27.4 | |
Net profit margin | % | 14.2 | 2.9 | 9.8 | 11.6 | 18.7 |
GSK PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 33,559 | 17,748 | 20,225 | 37,079 | 24,943 | |
Current liabilities | Rs m | 28,041 | 10,220 | 13,546 | 16,984 | 13,264 | |
Net working cap to sales | % | 17.6 | 23.3 | 22.8 | 61.3 | 35.9 | |
Current ratio | x | 1.2 | 1.7 | 1.5 | 2.2 | 1.9 | |
Inventory Days | Days | 351 | 42 | 51 | 91 | 97 | |
Debtors Days | Days | 141 | 113 | 269 | 229 | 216 | |
Net fixed assets | Rs m | 44,451 | 12,479 | 8,089 | 8,121 | 6,988 | |
Share capital | Rs m | 1,694 | 1,694 | 1,694 | 1,694 | 1,694 | |
"Free" reserves | Rs m | 19,704 | 16,512 | 13,089 | 24,936 | 15,735 | |
Net worth | Rs m | 21,398 | 18,206 | 14,783 | 26,630 | 17,430 | |
Long term debt | Rs m | 2 | 0 | 0 | 0 | 0 | |
Total assets | Rs m | 78,043 | 30,227 | 30,115 | 45,201 | 31,930 | |
Interest coverage | x | 1,233.3 | 49.3 | 129.6 | 391.3 | 462.6 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 0.4 | 1.1 | 1.0 | 0.7 | 1.0 | |
Return on assets | % | 5.7 | 3.3 | 9.7 | 8.5 | 19.1 | |
Return on equity | % | 20.8 | 5.1 | 19.4 | 14.3 | 34.9 | |
Return on capital | % | 31.9 | 17.1 | 31.0 | 29.3 | 48.1 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Imports to sales | % | 22.7 | 27.1 | 39.0 | 27.0 | 48.1 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 7,091 | 8,750 | 11,397 | 8,853 | 15,630 | |
Fx inflow | Rs m | 534 | 276 | 278 | 528 | 1,622 | |
Fx outflow | Rs m | 7,091 | 8,750 | 11,397 | 8,853 | 15,630 | |
Net fx | Rs m | -6,557 | -8,474 | -11,119 | -8,325 | -14,008 |
GSK PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 4,095 | 4,905 | 5,779 | 8,107 | 4,842 | |
From Investments | Rs m | -1,535 | -568 | 4,180 | -4,055 | 8,079 | |
From Financial Activity | Rs m | -3,584 | -4,276 | -6,956 | -5,242 | -15,433 | |
Net Cashflow | Rs m | -1,023 | 60 | 3,004 | -1,190 | -2,512 |
Share Holding
Shareholding as on Dec 2023
|
Company Information
|
CHM: R S Karnad | COMP SEC: Ajay Nadkarni | YEAR OF INC: 1924 | BSE CODE: 500660 | FV (Rs): 10 | DIV YIELD (%): 1.6 |
Read: GSK PHARMA 2022-23 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES ZYDUS LIFESCIENCES DR. REDDYS LAB SUN PHARMA CIPLA
Compare GSK PHARMA With: DIVIS LABORATORIES ZYDUS LIFESCIENCES DR. REDDYS LAB SUN PHARMA CIPLA
Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.